weekly biotechnology news wrap up

July 21, 2017

July 21, 2017

This week’s headlines include: Vertex Touts Positive Triple-Drug Data For Cystic Fibrosis Patients, Emergent Buys Sanofi Pasteur’s Smallpox Vaccine for Up-to-$125M, Puma to price new cancer med Nerlynx at a higher-than-expected $10K per month: report, Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimore, Gottlieb: FDA to Issue new Policies to Streamline Generic Reviews in 2017, and Scientists plan to trick Zika-carrying mosquitoes into breeding themselves out of existence.


Headlines:

“Vertex Touts Positive Triple-Drug Data For Cystic Fibrosis Patients,” Xconomy

“The Boston firm announced Tuesday that studies of three experimental drug combinations all reported notable improvement in patients who have a different underlying genetic pattern than patients already eligible for current commercial products. If all plays out well, up to 90 percent of people with CF could have a drug to treat their disease in a few years…”

“Emergent Buys Sanofi Pasteur’s Smallpox Vaccine for Up-to-$125M,” Genetic Engineering News

“Emergent BioSolutions has agreed to acquire the ACAM2000® [Smallpox (Vaccinia) Vaccine, Live] business of Sanofi Pasteur for up to $125 million cash, in a deal the buyer said would reinforce its strategic focus on treating public health threats…”

“Puma to price new cancer med Nerlynx at a higher-than-expected $10K per month: report,” FiercePharma

“Shares of Puma Biotechnology have tripled since the start of the year to more than $95, as the Los Angeles company gets set to launch its debut drug, Nerlynx (neratinib) for HER2-positive breast cancer. Now analysts are predicting premium pricing for the new drug that they believe will drive shares even higher…”

“Emergent BioSolutions to acquire anthrax treatment, move manufacturing to Baltimore,” Baltimore Sun

“Emergent BioSolutions, a Gaithersburg-based drug maker with facilities in Baltimore, has acquired a drug used to treat anthrax from GlaxoSmithKline in a deal worth up to $96 million…”

“Gottlieb: FDA to Issue new Policies to Streamline Generic Reviews in 2017,” Regulatory Focus

By the end of 2017, the US Food and Drug Administration (FDA) will issue two new documents to improve the review process for generic drugs, according to FDA Commissioner Scott Gottlieb...”

“Scientists plan to trick Zika-carrying mosquitoes into breeding themselves out of existence,” The Washington Post

“This summer, a Silicon Valley tech company will have millions of machine-raised, bacteria-infected mosquitoes packed into windowless white vans, driven inland and released into the wild — or, at least, the streets of Fresno, Calif. And, yes, Fresno County officials are encouraging this. It’s all part of the “Debug Fresno” project, which aims to cut down on the number of Aedes aegypti mosquitoes, an unwelcome invasive species that arrived in California’s Central Valley in 2013. In addition to being potential carriers of the Zika, dengue fever and chikungunya viruses, the Aedes aegypti also adapted rapidly to the area’s residential neighborhoods, to the chagrin of residents and officials alike…”